These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18490527)

  • 1. Embolic protection and platelet inhibition during renal artery stenting.
    Cooper CJ; Haller ST; Colyer W; Steffes M; Burket MW; Thomas WJ; Safian R; Reddy B; Brewster P; Ankenbrandt MA; Virmani R; Dippel E; Rocha-Singh K; Murphy TP; Kennedy DJ; Shapiro JI; D'Agostino RD; Pencina MJ; Khuder S
    Circulation; 2008 May; 117(21):2752-60. PubMed ID: 18490527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.
    Kanjwal K; Cooper CJ; Virmani R; Haller S; Shapiro JI; Burket MW; Steffes M; Brewster P; Zhang H; Colyer WR
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):16-23. PubMed ID: 20209644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete versus partial distal embolic protection during renal artery stenting.
    Kanjwal K; Haller S; Steffes M; Virmani R; Shapiro JI; Burket MW; Cooper CJ; Colyer WR
    Catheter Cardiovasc Interv; 2009 May; 73(6):725-30. PubMed ID: 19198007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of renal function in patients with renal artery stenosis.
    Yu H; Zhang D; Haller S; Kanjwal K; Colyer W; Brewster P; Steffes M; Shapiro JI; Cooper CJ
    Vasc Med; 2011 Oct; 16(5):331-8. PubMed ID: 21908683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis.
    Laird JR; Tehrani F; Soukas P; Joye JD; Ansel GM; Rocha-Singh K
    Catheter Cardiovasc Interv; 2012 Feb; 79(3):430-6. PubMed ID: 21805607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
    Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
    Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
    Kopp CW; Steiner S; Nasel C; Seidinger D; Mlekusch I; Lang W; Bartok A; Ahmadi R; Minar E
    Stroke; 2003 Nov; 34(11):2560-7. PubMed ID: 14563968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of embolic protection devices in renal artery stenting.
    Johnson CM; Hodgson KJ
    Perspect Vasc Surg Endovasc Ther; 2007 Sep; 19(3):266-71. PubMed ID: 17911553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting.
    Kakkar AK; Moustapha A; Hanley HG; Weiss M; Caldito G; Misra P; Reddy PC; Tandon N
    Catheter Cardiovasc Interv; 2004 Jan; 61(1):31-4. PubMed ID: 14696156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
    Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.